Jay Amin, MD
Cardiovascular Disease · Clearwater, FLNPI 1720077365
Payments from drug & device makers
Across 213 payments — averaging $3993.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$260K
- Janssen Research & Development, LLC$243K
- Eli Lilly$172K
- Kowa Research Institute, Inc.$63K
- AstraZeneca$57K
- Merck$41K
- plus $16K from 18 others
Across 1 payment — averaging $1119.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $259,672 |
| Janssen Research & Development, LLC | 32 | $242,744 |
| Eli Lilly | 9 | $172,022 |
| Kowa Research Institute, Inc. | 34 | $62,798 |
| AstraZeneca | 29 | $56,621 |
| Merck | 25 | $41,192 |
| E.r. Squibb & Sons, L.L.C. | 6 | $14,301 |
| Medtronic | 12 | $319 |
| Boston Scientific | 8 | $244 |
| Pfizer | 5 | $137 |
| Johnson & Johnson | 4 | $73 |
| Axonics, Inc. | 1 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $58 |
| Abbott | 2 | $50 |
| Astellas Pharma US Inc | 2 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Novartis | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Millicent US Inc | 1 | $20 |
| Heartflow, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$850,618 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Clearwater
- Jorge NavasClearwater$1.6M
- Jason ZelenkaClearwater$1.3M
- Marilyn KingClearwater$674K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.